Validation of the motion sickness severity scale: Secondary analysis of a randomized, double-blind, placebo-controlled study of a treatment for motion sickness.
<h4>Background</h4>Motion sickness is characterized by nausea and vomiting among a constellation of symptoms. Symptom severity is dynamic and distressing. Most validated motion sickness scales are time-intensive and effortful, with alternative scales having uncertain performance or non-s...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0280058 |
| _version_ | 1797866002600427520 |
|---|---|
| author | Mark É Czeisler Justina M Pruski Pan Wang Jingyuan Wang Changfu Xiao Mihael H Polymeropoulos Vasilios M Polymeropoulos |
| author_facet | Mark É Czeisler Justina M Pruski Pan Wang Jingyuan Wang Changfu Xiao Mihael H Polymeropoulos Vasilios M Polymeropoulos |
| author_sort | Mark É Czeisler |
| collection | DOAJ |
| description | <h4>Background</h4>Motion sickness is characterized by nausea and vomiting among a constellation of symptoms. Symptom severity is dynamic and distressing. Most validated motion sickness scales are time-intensive and effortful, with alternative scales having uncertain performance or non-specific measures. A validated instrument allowing for facile, rapid assessment of core motion sickness symptom severity would therefore be valuable. We assessed the performance of the Motion Sickness Severity Scale (MSSS), a six-item questionnaire designed to measure real-time motion sickness symptoms.<h4>Methods</h4>MSSS construct validity was assessed as a secondary analysis of data from 63 healthy participants without antiemetic treatment in a clinical trial (Unique Identifier = NCT03772340) conducted to evaluate the safety and efficacy of Tradipitant-a novel neurokinin-1 receptor antagonist-in the treatment of motion sickness. Clinical outcome assessments included the MSSS, the Patient Global Impression of Severity (PGI-S), and the Motion Sickness Assessment Questionnaire (MSAQ). The performance of the MSSS through Pearson correlation coefficients, within-group analysis of variance, empirical cumulative distribution functions, and Kolmogorov-Smirnov tests.<h4>Results</h4>The MSSS correlated very highly with the PGI-S (r = 0.93, p-value<0.0001) and highly with the MSAQ (r = 0.83, p-value<0.0001). Mean MSSS scores between increasing PGI-S severity levels increased significantly in all four increments (None-to-Mild: p-value = 0.006, Mild-to-Moderate: p-value<0.0001, Moderate-to-Severe: p-value = 0.006, Severe-to-Very-Severe: p-value = 0.002). There were statistically significant differences in MSSS score distributions stratified by PGI-S severity level, with higher MSSS scores associated with higher PGI-S severity levels and lower MSSS scores associated with lower PGI-S severity levels.<h4>Discussion</h4>The MSSS is a valid instrument for the assessment of the core motion sickness symptoms and is reflective of global disease severity. Implementation of the MSSS and comparable simplified, short questionnaires in motion sickness research will provide rapid and accurate measures of disease severity. These measures will enable further elucidation of motion sickness as an illness and inform the development and evaluation of motion sickness therapies. |
| first_indexed | 2024-04-09T23:17:04Z |
| format | Article |
| id | doaj.art-057d00d7b3d240808b5c60c04d00cab1 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-09T23:17:04Z |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-057d00d7b3d240808b5c60c04d00cab12023-03-22T05:31:27ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01181e028005810.1371/journal.pone.0280058Validation of the motion sickness severity scale: Secondary analysis of a randomized, double-blind, placebo-controlled study of a treatment for motion sickness.Mark É CzeislerJustina M PruskiPan WangJingyuan WangChangfu XiaoMihael H PolymeropoulosVasilios M Polymeropoulos<h4>Background</h4>Motion sickness is characterized by nausea and vomiting among a constellation of symptoms. Symptom severity is dynamic and distressing. Most validated motion sickness scales are time-intensive and effortful, with alternative scales having uncertain performance or non-specific measures. A validated instrument allowing for facile, rapid assessment of core motion sickness symptom severity would therefore be valuable. We assessed the performance of the Motion Sickness Severity Scale (MSSS), a six-item questionnaire designed to measure real-time motion sickness symptoms.<h4>Methods</h4>MSSS construct validity was assessed as a secondary analysis of data from 63 healthy participants without antiemetic treatment in a clinical trial (Unique Identifier = NCT03772340) conducted to evaluate the safety and efficacy of Tradipitant-a novel neurokinin-1 receptor antagonist-in the treatment of motion sickness. Clinical outcome assessments included the MSSS, the Patient Global Impression of Severity (PGI-S), and the Motion Sickness Assessment Questionnaire (MSAQ). The performance of the MSSS through Pearson correlation coefficients, within-group analysis of variance, empirical cumulative distribution functions, and Kolmogorov-Smirnov tests.<h4>Results</h4>The MSSS correlated very highly with the PGI-S (r = 0.93, p-value<0.0001) and highly with the MSAQ (r = 0.83, p-value<0.0001). Mean MSSS scores between increasing PGI-S severity levels increased significantly in all four increments (None-to-Mild: p-value = 0.006, Mild-to-Moderate: p-value<0.0001, Moderate-to-Severe: p-value = 0.006, Severe-to-Very-Severe: p-value = 0.002). There were statistically significant differences in MSSS score distributions stratified by PGI-S severity level, with higher MSSS scores associated with higher PGI-S severity levels and lower MSSS scores associated with lower PGI-S severity levels.<h4>Discussion</h4>The MSSS is a valid instrument for the assessment of the core motion sickness symptoms and is reflective of global disease severity. Implementation of the MSSS and comparable simplified, short questionnaires in motion sickness research will provide rapid and accurate measures of disease severity. These measures will enable further elucidation of motion sickness as an illness and inform the development and evaluation of motion sickness therapies.https://doi.org/10.1371/journal.pone.0280058 |
| spellingShingle | Mark É Czeisler Justina M Pruski Pan Wang Jingyuan Wang Changfu Xiao Mihael H Polymeropoulos Vasilios M Polymeropoulos Validation of the motion sickness severity scale: Secondary analysis of a randomized, double-blind, placebo-controlled study of a treatment for motion sickness. PLoS ONE |
| title | Validation of the motion sickness severity scale: Secondary analysis of a randomized, double-blind, placebo-controlled study of a treatment for motion sickness. |
| title_full | Validation of the motion sickness severity scale: Secondary analysis of a randomized, double-blind, placebo-controlled study of a treatment for motion sickness. |
| title_fullStr | Validation of the motion sickness severity scale: Secondary analysis of a randomized, double-blind, placebo-controlled study of a treatment for motion sickness. |
| title_full_unstemmed | Validation of the motion sickness severity scale: Secondary analysis of a randomized, double-blind, placebo-controlled study of a treatment for motion sickness. |
| title_short | Validation of the motion sickness severity scale: Secondary analysis of a randomized, double-blind, placebo-controlled study of a treatment for motion sickness. |
| title_sort | validation of the motion sickness severity scale secondary analysis of a randomized double blind placebo controlled study of a treatment for motion sickness |
| url | https://doi.org/10.1371/journal.pone.0280058 |
| work_keys_str_mv | AT markeczeisler validationofthemotionsicknessseverityscalesecondaryanalysisofarandomizeddoubleblindplacebocontrolledstudyofatreatmentformotionsickness AT justinampruski validationofthemotionsicknessseverityscalesecondaryanalysisofarandomizeddoubleblindplacebocontrolledstudyofatreatmentformotionsickness AT panwang validationofthemotionsicknessseverityscalesecondaryanalysisofarandomizeddoubleblindplacebocontrolledstudyofatreatmentformotionsickness AT jingyuanwang validationofthemotionsicknessseverityscalesecondaryanalysisofarandomizeddoubleblindplacebocontrolledstudyofatreatmentformotionsickness AT changfuxiao validationofthemotionsicknessseverityscalesecondaryanalysisofarandomizeddoubleblindplacebocontrolledstudyofatreatmentformotionsickness AT mihaelhpolymeropoulos validationofthemotionsicknessseverityscalesecondaryanalysisofarandomizeddoubleblindplacebocontrolledstudyofatreatmentformotionsickness AT vasiliosmpolymeropoulos validationofthemotionsicknessseverityscalesecondaryanalysisofarandomizeddoubleblindplacebocontrolledstudyofatreatmentformotionsickness |